Profound Medical (PROF) EBIT (2024 - 2026)

Profound Medical's EBIT history runs 3 years deep, the most recent figure standing at -$8.0 million for Q1 2026.

• In Q1 2026, EBIT rose 28.17% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$3.2 million (up 91.19% YoY), while the FY2025 annual figure was -$6.3 million, up 80.8% from the prior year.
• EBIT was -$8.0 million for Q1 2026 at Profound Medical, down from $27.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $27.5 million in Q4 2025 to a low of -$13.8 million in Q2 2025.
• Historically, EBIT has averaged -$5.3 million across 3 years, with a median of -$8.3 million in 2024.
• Biggest YoY gain for EBIT was 429.98% in 2025; the steepest drop was 76.05% in 2025.
• A 3-year view of EBIT shows it stood at -$8.3 million in 2024, then jumped by 429.98% to $27.5 million in 2025, then sank by 129.13% to -$8.0 million in 2026.
• The last three EBIT figures came in at -$8.0 million (Q1 2026), $27.5 million (Q4 2025), and -$8.9 million (Q3 2025), per Business Quant data.